Ani Pharmaceuticals Stock Alpha and Beta Analysis
| ANIP Stock | USD 66.52 0.52 0.79% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as ANI Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in ANI Pharmaceuticals over a specified time horizon. Remember, high ANI Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to ANI Pharmaceuticals' market risk premium analysis include:
Beta 0.77 | Alpha 0.26 | Risk 2.03 | Sharpe Ratio 0.13 | Expected Return 0.27 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
ANI |
ANI Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. ANI Pharmaceuticals market risk premium is the additional return an investor will receive from holding ANI Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in ANI Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate ANI Pharmaceuticals' performance over market.| α | 0.26 | β | 0.77 |
ANI Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of ANI Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how ANI Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.ANI Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how ANI Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading ANI Pharmaceuticals shares will generate the highest return on investment. By understating and applying ANI Pharmaceuticals stock market price indicators, traders can identify ANI Pharmaceuticals position entry and exit signals to maximize returns.
ANI Pharmaceuticals Return and Market Media
The median price of ANI Pharmaceuticals for the period between Thu, Feb 1, 2024 and Wed, May 1, 2024 is 65.81 with a coefficient of variation of 7.87. The daily time series for the period is distributed with a sample standard deviation of 4.99, arithmetic mean of 63.49, and mean deviation of 4.49. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 1261 shares by Christopher Mutz of ANI Pharmaceuticals at 57.55 subject to Rule 16b-3 | 02/15/2024 |
2 | Acquisition by Shanmugam Muthusamy of 13421 shares of ANI Pharmaceuticals subject to Rule 16b-3 | 02/16/2024 |
3 | ANI Pharmaceuticals SVP CFO Sold 510K In Company Stock | 03/12/2024 |
4 | Disposition of 17455 shares by Nikhil Lalwani of ANI Pharmaceuticals at 69.58 subject to Rule 16b-3 | 03/22/2024 |
5 | Axsomes Narcolepsy Drug Study Meets Primary Goal | 03/26/2024 |
6 | Disposition of 3653 shares by James Marken of ANI Pharmaceuticals at 69.58 subject to Rule 16b-3 | 03/28/2024 |
7 | AstraZenecas Imfinzi Improves Survival in SCLC Study | 04/05/2024 |
8 | With 64 percent ownership of the shares, ANI Pharmaceuticals, Inc. is heavily dominated by institutional owners | 04/12/2024 |
9 | Why ANI is Poised to Beat Earnings Estimates Again | 04/15/2024 |
10 | Marinus Down 83 percent on Lead Drug Falling Short in Seizure Study | 04/16/2024 |
11 | Disposition of 9520 shares by Shanmugam Muthusamy of ANI Pharmaceuticals at 65.4 subject to Rule 16b-3 | 04/17/2024 |
12 | ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 830 a.m. ET | 04/18/2024 |
13 | Ani Pharmaceuticals executive sells over 1.7m in company stock | 04/22/2024 |
14 | Merck Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales | 04/25/2024 |
15 | Sage Therapeutics Q1 Earnings Miss, Sales Beat Estimates | 04/26/2024 |
16 | Disposition of 13502 shares by Ori Gutwerg of ANI Pharmaceuticals at 62. subject to Rule 16b-3 | 04/30/2024 |
About ANI Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including ANI or other stocks. Alpha measures the amount that position in ANI Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 (projected) | Dividend Yield | 0.002484 | 0.001637 | 0.001186 | Price To Sales Ratio | 2.07 | 2.04 | 1.94 |
ANI Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of ANI Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ANI Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of ANI Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of ANI Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of ANI Pharmaceuticals' management manipulating its earnings.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with ANI Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out ANI Pharmaceuticals Backtesting, ANI Pharmaceuticals Valuation, ANI Pharmaceuticals Correlation, ANI Pharmaceuticals Hype Analysis, ANI Pharmaceuticals Volatility, ANI Pharmaceuticals History and analyze ANI Pharmaceuticals Performance. To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for ANI Stock analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |
ANI Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.